Home › 2016 › March

Month: March 2016

By Posted on Posted in Adverse Drug Reaction [ADR], PubMed Entry, Thasso Post, Theragenomic Medicine Tagged with , , , , , , ,

Last Updated on March 26, 2016 by Joseph Gut – thasso Barr PM, Saylors GB, Spurgeon SE, Cheson BD, Greenwald DR, O’Brien SM, Liem AK, McIntyre RE, Joshi A, Abella-Dominicis E, Hawkins MJ, Reddy A, Di Paolo J, Lee H, …

Clinical phase 2 study of idelalisib and entospletinib: pneumonitis limits combination therapy in relapsed refractory CLL and NHL Read more »

By Posted on Posted in New Safety Information, Thasso Post, Theragenomic Medicine Tagged with , , ,

Last Updated on March 24, 2016 by Joseph Gut – thasso March 23, 2016 –  The present announcement by the American Food and Drug Administration (FDA) needs no further commentary and is reprinted here without editing as follows: __________ In …

Opioids and their related risks of misuse, abuse, addiction, overdose and death: FDA announces enhanced warnings for immediate-release opioid pain medications Read more »

By Posted on Posted in Adverse Drug Reaction [ADR], New Safety Information, Thasso Post, Theragenomic Medicine Tagged with , , , , , , , ,

Last Updated on March 20, 2016 by Joseph Gut – thasso  March 20, 2016 – The European Medicines Agency (EMA) has, at the request of the European Commission, has started a review of the cancer medicine Idelalisib (Zydelig), which is authorised in the …

Under scrutiny: The EMA reviews cancer medicine Idelalisib (Zydelig) after the occurrence of serious adverse effects, some of them fatal, in three clinical trials Read more »

By Posted on Posted in Personalized Medicine, Regulatory Approval, Thasso Post, Theragenomic Medicine Tagged with , , , , , ,

Last Updated on March 14, 2016 by Joseph Gut – thasso March 14, 2015 – The American Food and Drug Administration (FDA) just approved Crizotinib (Xalkori) to treat the patient subpopulation with advanced (metastatic) non-small cell lung cancer (NSCLC) whose …

The use of Crizotinib (Xalkori) has been expanded to treat advanced NSCLC in the patient group who carries a ROS-1 gene alteration Read more »

By Posted on Posted in Commentary, On The Horizon, Thasso Post, Theragenomic Medicine Tagged with , , , , , , , ,

Last Updated on March 12, 2016 by Joseph Gut – thasso [avatar user=”thassodotcom” size=”thumbnail” align=”left” /] March 11, 2016 – Medscape Multispeciality just published  a CDC Expert Commentary by John W. Ward, MD, Director, Division of Viral Hepatitis, Centers for Disease Control and …

Extraorbitant cost keeps HCV care out of reach for many patients: Are there profound ethical and societal issues looming? Read more »

By Posted on Posted in PubMed Entry, Thasso Post, Theragenomic Medicine Tagged with , , , , , , , , ,

Last Updated on March 11, 2016 by Joseph Gut – thasso Feld JJ, Jacobson IM, Hézode C, Asselah T, Ruane PJ, Gruener N, Abergel A, Mangia A, Lai CL, Chan HL, Mazzotta F, Moreno C, Yoshida E, Shafran SD, Towner …

Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection Read more »

By Posted on Posted in Adverse Drug Reaction [ADR], PubMed Entry Tagged with , ,

Last Updated on March 8, 2016 by Joseph Gut – thasso Fukuizumi A, Miyanaga A, Seike M, Kato Y, Nakamichi S, Chubachi K, Matsumoto M, Noro R, Minegishi Y, Kunugi S, Kubota K, Gemma A BMC Res Notes 2015;8:165 PMID: …

Effective Crizotinib schedule for an elderly patient with ALK rearranged non-small-cell lung cancer: a case report Read more »

By Posted on Posted in Regulatory Approval, Thasso Post Tagged with , , , , , , ,

Last Updated on March 4, 2016 by Joseph Gut – thasso March 04, 2016 –  On February 25, 2016, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Ixekizumab (Taltz), …

Ixekizumab (Taltz) for plaque psoriasis: Positive opinion by the European CHMP Read more »